Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 6/20 | 0.42 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.41 |
| ▸ | ACACA | Q13085 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 4/20 | 0.39 |
| ▸ | FPR2 | P25090 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31206034 | 0.88 | DRD2 (0.44) | DRD2PBKACACBNPC1L1ACACA | |
| SCHEMBL31206120 | 0.86 | KDM1A (0.46) | DRD2NPC1L1NAMPTALDH1A1 | |
| SCHEMBL31206141 | 0.85 | ACACB (0.44) | DRD2PBKACACBACACA | |
| SCHEMBL25041510 | 0.85 | ACACB (0.44) | DRD2PBKACACBACACA | |
| SCHEMBL25041407 | 0.84 | TDP1 (0.44) | FPR3FPR2ALDH1A1 | |
| SCHEMBL31206142 | 0.81 | DRD2 (0.47) | DRD2PBKACACBACACANAMPT | |
| SCHEMBL31206152 | 0.81 | DRD2 (0.55) | DRD2ACACBACACA | |
| SCHEMBL31206107 | 0.79 | ALDH1A1 (0.60) | DRD2PBKACACBACACANAMPT | |
| SCHEMBL31206233 | 0.79 | MDM2 (0.49) | DRD2PBKACACBACACAALDH1A1 | |
| SCHEMBL31206293 | 0.79 | DDB1 (0.46) | DRD2NPC1L1NAMPTFPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
| WO-2023016447-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | DRD2 4708/4885PBK 4573/4885ACACB 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.